Global Endometriosis Drugs Market 2016-2020

  • ID: 3776383
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer HealthCare
  • Euroscreen
  • Neurocrine Biosciences
  • Pfizer
  • Roivant Sciences
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About the Endometriosis Market

Endometriosis is a common health condition in women where the endometrial tissue, which is found in the lining of the uterus, appears and grows outside the uterine cavity. The endometrial tissue is shed from the body during menstruation.

The tissue growing outside the uterine cavity is called endometrial implants. Endometriosis can also occur in the fallopian tubes, ovaries, pelvic cavity, vagina, cervix, and bladder. In rare cases, it has been reported in other parts of the body such as the lungs, brain, and skin. These implants are usually benign in nature. Women of reproductive age are often affected by this condition.

Endometriosis often occurs due to retrograde menstruation, where the menstrual blood flows back into the pelvic cavity instead of leaving the body. This then adheres to the surface of the bladder, ovaries, or rectum and continues to grow or thicken over the course of each menstrual cycle.

The analysts forecast the global endometriosis market to grow at a CAGR of 2.05% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global endometriosis market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of approved and off-label branded and generic drugs used for the treatment and prevention of endometriosis and related pain. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Endometriosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- AstraZeneca
- Bayer HealthCare
- Pfizer

Other prominent vendors
- Addex Therapeutics
- Astellas Pharma
- Debiopharm
- ElexoPharm
- Endoceutics
- Euroscreen
- Forendo Pharma
- Isifer
- Kissei Pharmaceutical
- Neurocrine Biosciences
- Nippon Shinyaku
- ObsEva
- Orphagen Pharmaceuticals
- Philogen
- PregLem
- Repros Therapeutics
- Roivant Sciences
- SK Chemicals
- Speciality European Pharma
- SYNG Pharmaceuticals
- Takeda
- United Pharmaceuticals
- ValiPharma

Market drivers
- Increased adoption of OCPs

Market challenges
- Surgeries as primary treatment option

Market trends
- Increased focus on intrauterine devices (IUDs)

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer HealthCare
  • Euroscreen
  • Neurocrine Biosciences
  • Pfizer
  • Roivant Sciences
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Endometriosis: An overview
PART 05: Pipeline analysis
  • Pipeline molecules based on their mechanism
PART 06: Key buying criteria for endometriosis drugs

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by type of therapy
  • Hormone therapy
  • Market size and forecast
  • Pain medications
  • Market size and forecast
PART 09: Market segmentation by ROA
  • Oral
  • Parenteral
  • Intrauterine systems
  • Nasal spray
PART 10: Geographical segmentation
  • Global endometriosis drugs market by geography 2015-2020
  • Endometriosis drugs market in Americas
  • Endometriosis drugs market in EMEA
  • Endometriosis drugs market in APAC
PART 11: Market drivers
  • Recurrence of endometriosis
  • Increased adoption on OCPs
  • Ineffective existing therapies leading to high unmet need
PART 12: Impact of drivers

PART 13: Market challenges
  • Poor compliance rates leading to high dropouts
  • Surgeries as primary treatment option
  • Unavailability of proper diagnostic tools
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Replacement of GnRH agonists by GnRH antagonists
  • Increased focus on IUDs
  • Development of novel targets for treatment
PART 16: Vendor landscape
  • Competitive scenario
  • Key news
  • Major upcoming vendors
PART 17: Key vendor analysis
  • AbbVie
  • AstraZeneca
  • Bayer HealthCare
  • Pfizer
  • Other prominent vendors
PART 18: Appendix
  • List of abbreviations
PART 19: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Pipeline portfolio: Global endometriosis drugs market
Exhibit 03: Segmentation of pipeline molecules in different stages of development
Exhibit 04: Segmentation of pipeline molecules based on their mechanism of action
Exhibit 05: Impact of GnRH antagonists on global endometriosis market
Exhibit 06: Competitive assessment of marketed and late-stage pipeline molecules
Exhibit 07: Key buying criteria for endometriosis drugs
Exhibit 08: Global endometriosis market snapshot: Developed and emerging markets 2015
Exhibit 09: Global endometriosis drugs market 2015-2020 ($ billions)
Exhibit 10: Opportunity analysis: Global endometriosis drugs market
Exhibit 11: Five forces analysis
Exhibit 12: Segmentation of global endometriosis drugs market by type of therapy
Exhibit 13: Global endometriosis market segmentation by type of therapy 2015
Exhibit 14: Hormone therapies market for endometriosis 2015-2020 ($ billions)
Exhibit 15: Pain medications market for endometriosis 2015-2020 ($ millions)
Exhibit 16: Global endometriosis market by type of therapy 2015-2020
Exhibit 17: Global endometriosis drugs market by geography 2015-2020
Exhibit 18: Segmentation of global endometriosis drugs market by geography 2015 and 2020
Exhibit 19: Segmentation of global endometriosis drugs market by geography 2015-2020 ($ millions)
Exhibit 20: Global endometriosis market by geography 2015-2020
Exhibit 21: Endometriosis drugs market in Americas 2015-2020 ($ millions)
Exhibit 22: Endometriosis prevalence in EMEA
Exhibit 23: Endometriosis drugs market in EMEA 2015-2020 ($ millions)
Exhibit 24: Endometriosis drugs market in APAC 2015-2020 ($ millions)
Exhibit 25: Impact of drivers
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Market share of top vendors in global endometriosis drugs market 2015
Exhibit 28: Geographical presence of major vendors in global endometriosis market
Exhibit 29: Competitive scenario of vendors in global endometriosis market 2015-2020
Exhibit 30: Major upcoming vendors in global endometriosis market
Exhibit 31: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)
Exhibit 32: AbbVie: Geographical segmentation of Lupron by revenue 2015
Exhibit 33: AbbVie: Metrics analysis
Exhibit 34: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions)
Exhibit 35: AstraZeneca: Geographic segmentation of Zoladex 2015
Exhibit 36: AstraZeneca: Metrics analysis
Exhibit 37: Bayer: YoY revenue and growth rate of Mirena 2013-2015 ($ billions)
Exhibit 38: Bayer HealthCare: Metrics analysis
Exhibit 39: Pfizer: YoY revenue and growth rate of Depo-Provera 2013-2015 ($ millions)
Exhibit 40: Pfizer: Metrics analysis
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer HealthCare
  • Euroscreen
  • Neurocrine Biosciences
  • Pfizer
  • Roivant Sciences
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: - Global Endometriosis Market 2016-2020

The author of the report recognizes the following companies as the key players in the global endometriosis market: AbbVie, AstraZeneca, Bayer HealthCare, and Pfizer.

Other Prominent Vendors in the market are: Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, Endoceutics, Euroscreen, Forendo Pharma, Isifer, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, ObsEva, Orphagen Pharmaceuticals, Philogen, PregLem, Repros Therapeutics, Roivant Sciences, SK Chemicals, Speciality European Pharma, SYNG Pharmaceuticals, Takeda, United Pharmaceuticals, and ValiPharma.

Commenting on the report, an analyst from the research team said: “A trend boosting market growth is the increased focus on IUDs. Current treatment for endometriosis includes the use of GnRH agonists and oral contraceptives along with the use of surgeries. However, all these therapies are associated with many unwanted side effects due to hormonal changes in the body along with the early recurrence of the disease. Hence, the need for an effective replacement for these conventional therapies has led to the development of IUDs. Though IUDs were initially developed for effective birth control, their use has been extended to treat endometriosis. Levonorgestrel intrauterine system (LNG-IUS) devices such as Mirena and Skyla will release progestogen into the body through the IUD at low concentration for an extended period.”

According to the report, a key growth driver is the increased adoption of OCPs. OCPs also referred to as hormonal pills contain the female hormones, estrogen and progestin similar to that produced by the ovaries. Some of the pills may contain only progestin. Apart from being used as contraceptives, these hormone pills are found to be effective in treating endometriosis. They do not cure endometriosis but are helpful in controlling the pain and preventing the condition from worsening. These medicines are also found to lower the chances of getting endometrial and ovarian cancer, ovarian cysts, certain breast lumps, and also protects the individual from osteoporosis.

Further, the report states that one challenge that could hamper market growth is surgery as the primary treatment option.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

- AbbVie
- AstraZeneca
- Bayer HealthCare
- Pfizer
- Addex Therapeutics
- Astellas Pharma
- Debiopharm
- ElexoPharm
- Endoceutics
- Euroscreen
- Forendo Pharma
- Isifer
- Kissei Pharmaceutical
- Neurocrine Biosciences
- Nippon Shinyaku
- ObsEva
- Orphagen Pharmaceuticals
- Philogen
- PregLem
- Repros Therapeutics
- Roivant Sciences
- SK Chemicals
- Speciality European Pharma
- SYNG Pharmaceuticals
- Takeda
- United Pharmaceuticals
- ValiPharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll